论文部分内容阅读
目的:探讨培美曲塞联合顺铂治疗局部晚期肺腺癌的临床治疗效果。方法:本实验选取在2010年9月份到2010年12月份到我院肿瘤科进行治疗的晚期肺腺癌患者80例为对象,随把所有患者机分为40例观察组(培美曲塞+顺铂治疗组)和40例对照组(多西他赛+顺铂治疗组),后进行统计和观察比较两组患者的临床治疗情况。结果:80例患者均有不同程度的临床症状改善表现。观察组治疗总有效率为42.5%,对照组治疗总有效率为37.5%,比较两组近期疗效,P>0.05,差异无统计学意义;两组均有轻重不同的不良反应发生,主要表现在骨髓抑制(中性粒细胞下降、血小板下降、血红蛋白下降)、胃肠道反应(恶心、呕吐、腹泻)、肝肾功能损害(谷丙转氨酶升高、尿素氮升高)及皮疹或脱发等方面,观察组在不良反应发生率和不良反应表现程度方面均明显高于对照组,两者差异比较有统计学意义(P<0.05)。结论:治疗晚期肺腺癌时采用培美曲塞+顺铂治疗方法可以取得较好的疗效,能够改善患者的临床表现,明显减少毒性反应,值得在临床中推广和应用,可用于治疗晚期肺腺癌的一线用药。
Objective: To investigate the clinical effect of pemetrexed combined with cisplatin in the treatment of locally advanced lung adenocarcinoma. Methods: Eighty patients with advanced lung adenocarcinoma who were treated in Department of Oncology in our hospital from September 2010 to December 2010 were enrolled in this study. All patients were divided into 40 observation groups (pemetrexed + Cisplatin treatment group) and 40 control group (docetaxel plus cisplatin treatment group), after the statistics and observation of the clinical treatment of two groups of patients. Results: All 80 patients had different degrees of improvement of clinical symptoms. The total effective rate was 42.5% in the observation group and 37.5% in the control group. There was no significant difference in the short-term curative effect between the two groups (P> 0.05). There were significant differences in adverse reactions between the two groups Myelosuppression (neutropenia, thrombocytopenia, hemoglobin decline), gastrointestinal reactions (nausea, vomiting, diarrhea), impaired liver and kidney function (elevated alanine aminotransferases, elevated urea nitrogen) and rashes or hair loss , The observation group in the incidence of adverse reactions and adverse reactions were significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion: The treatment of advanced lung adenocarcinoma with pemetrexed + cisplatin treatment can achieve better efficacy, can improve the clinical manifestations of patients, significantly reduce the toxicity, it is worth to promote and apply in the clinic, can be used to treat advanced lung First-line treatment of adenocarcinoma.